Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 11:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Platelet inhibitors Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

NCT06933056
View directory record Official record
Conditions
Platelet Function and Reactivity Tests
Interventions
Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 16, 2026, 11:49 AM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 16, 2026, 11:49 AM EDT
Completed No phase listed Observational

Type 2 Diabetes With Antiplatelet Drugs

NCT05053828
View directory record Official record
Conditions
Type2 Diabetes, Antiplatelet Drugs, Myocardial Infarction, Heart Failure
Interventions
Antiplatelet Drug
Drug
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
173,464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 4 Interventional Results available

Reducing Total Cardiovascular Risk in an Urban Community

NCT00241904
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Interventions
Lifestyle Changes, Antiplatelet Agents, Beta Blocker, ACE Inhibitors
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 16, 2026, 11:49 AM EDT
Recruiting Phase 4 Interventional

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

NCT03968393
View directory record Official record
Conditions
Stroke, Atrial Fibrillation
Interventions
Non-vitamin K oral anticoagulant (NOAC)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
2,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

NCT04498273
View directory record Official record
Conditions
COVID-19
Interventions
Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo
Drug
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 80 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
71
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Not applicable Interventional Results available

Randomized On-X Anticoagulation Trial

NCT00291525
View directory record Official record
Conditions
Heart Valve Disease
Interventions
On-X valve using reduced anticoagulation, On-X Valve with Standard warfarin Therapy
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
44
States / cities
Tucson, Arizona • Loma Linda, California • Hartford, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Not applicable Interventional

IU Health Krannert Personalized Medicine Study

NCT02955121
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prescriber Access to Genetic Information
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607
View directory record Official record
Conditions
Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac Tromethamine 30 MG/ML, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 16, 2026, 11:49 AM EDT
Completed No phase listed Observational

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

NCT02362659
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 2 Interventional Results available

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

NCT02561000
View directory record Official record
Conditions
Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions
PZ-128, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 16, 2026, 11:49 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 16, 2026, 11:49 AM EDT
Not listed Phase 4 Interventional

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

NCT01869309
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Not applicable Interventional Results available

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

NCT01731041
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 16, 2026, 11:49 AM EDT
Not listed No phase listed Observational

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441
View directory record Official record
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 16, 2026, 11:49 AM EDT
Withdrawn Phase 2 Interventional

Ticagrelor vs. Prasugrel Effects on Infarct Size

NCT02507323
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ticagrelor, prasugrel, Placebo
Drug
Lead sponsor
Yochai Birnbaum
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 16, 2026, 11:49 AM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152
View directory record Official record
Conditions
Cardiovascular Diseases, Acute Coronary Syndrome
Interventions
clopidogrel, prasugrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Newark, Delaware • Baltimore, Maryland • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 16, 2026, 11:49 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 16, 2026, 11:49 AM EDT
Enrolling by invitation Phase 3 Interventional

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Selatogrel, Placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
81
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 16, 2026, 11:49 AM EDT